Manager TitleAgeSince
Chief Operating Officer - 13/11/2022
Director TitleAgeSince
Director/Board Member 61 15/08/2005
Chairman 67 18/09/2014
Director/Board Member 55 04/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-23.37%-37.69% - - 1.28M
+1.69%+3.22%+72.51%+130.97% 56.21B
+0.55%+8.49%+77.09%+100.93% 55.38B
+0.93%+4.11%-12.64%-12.98% 23.75B
+0.36%+3.42%+9.61%+407.11% 23.19B
+3.64%+8.34%+39.81%-5.88% 18.14B
+1.24%+6.04%+40.82%-29.62% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.86B
-0.83%+2.06%+23.70%+182.37% 13.56B
+7.20%+13.33%+42.13% - 12.97B
Average -0.71%+6.94%+51.99%+139.68% 26.21B
Weighted average by Cap. +1.48%+6.60%+56.46%+131.95%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14